DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Individual Patient Expanded Access 

Investigational New Drug Application (IND)

(Title 21, Code of Federal Regulations (CFR) Part 312)

Form Approved: OMB No. 0910-0814

Expiration Date: June 30, 2025

See PRA Statement on last page.

FORM FDA 3926 (7/22) Page 1 of 3 PSC Publishing Services (301) 443-6740 EF

Select this box if this form is an 

initial submission for an individual 

patient expanded access IND, 

and complete only fields 4 

through 8, and fields 10 and 11.

Select this box if this form accompanies 

a follow-up submission to an existing 

individual patient expanded access IND, 

and complete the items to the right in this 

section, and fields 8 through 11.

2. Date of Submission (mm/dd/yyyy)

Investigational Drug Name

Physician’s IND Number

3.b. Follow-Up Submission

1. Patient’s Initials

3.a. Initial Submission

3. Type of Submission

NOTE: Checking box 3a or 3b will “turn on” ONLY the fields that must be completed.

4. Clinical Information

Indication

Brief Clinical History (Patient’s age, gender, weight, allergies, diagnosis, prior therapy, response to prior therapy, reason for

request, including an explanation of why the patient lacks other therapeutic options)

5. Treatment Information

Investigational Drug Name

Name of the entity that will supply the drug (generally the manufacturer)

FDA Review Division (if known)

Treatment Plan (Including the dose, route and schedule of administration, planned duration, and monitoring procedures. Also include

modifications to the treatment plan in the event of toxicity.)
FORM FDA 3926 (7/22) Page 2 of 3

7. Physician’s Qualification Statement (Including medical school attended, year of graduation, medical specialty, state medical 

license number, current employment, and job title. Alternatively, attach the first few pages of physician’s curriculum vitae (CV), 

provided they contain this information. If attaching the CV electronically, use normal PDF functions for file attachments.)

8. Physician Name, Address, and Contact Information

Address 1 (Street address, No P.O. boxes)

Physician Name (Sponsor)

Address 2 (Apartment, suite, unit, building, floor, etc.)

City

ZIP Code

State

Email Address of Physician

Telephone Number of Physician

Facsimile (FAX) Number of Physician

Physician’s IND number, if known 

Initial Written IND Safety Report

Follow-up to a Written IND Safety Report

Annual Report

Summary of Expanded Access Use (treatment completed)

Change in Treatment Plan

General Correspondence

Response to FDA Request for Information

Response to Clinical Hold

9. Contents of Submission

This submission contains the following materials, which are attached to this form (select all that apply). If none of the following apply to the 

follow-up communications, use Form FDA 1571 for your submission.

I request authorization to submit this Form FDA 3926 to comply with FDA’s requirements for an individual patient expanded access IND.

10.a. Request for Authorization to Use Form FDA 3926

I request authorization to obtain concurrence by the Institutional Review Board (IRB) chairperson or by a designated IRB member, before 

the treatment use begins, in order to comply with FDA's requirements for IRB review and approval. This concurrence would be in lieu of 

review and approval at a convened IRB meeting at which a majority of the members are present. 

10.b. Request for Authorization to Use Alternative IRB Review Procedures

11. Certification Statement: I will not begin treatment until 30 days after FDA’s receipt of a completed application and all

required materials unless I receive earlier notification from FDA that treatment may begin. I also agree not to begin or 

continue clinical investigations covered by the IND if those studies are placed on clinical hold. I also certify that I will obtain 

informed consent, and that an Institutional Review Board (IRB) will be responsible for initial and continuing review and 

approval of this treatment use, consistent with applicable FDA requirements. I understand that in the case of an emergency 

request, treatment may begin without prior IRB approval, provided the IRB is notified of the emergency treatment within 5 

working days of treatment. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.

WARNING: A willfully false statement is a criminal offense (U.S.C. Title 18, Sec. 1001).

Signature of Physician Date

Date of FDA Receipt

IND Number

For FDA Use Only

Is this an emergency individual patient IND? Is this indication for a rare disease (prevalence 

< 200,000 in the U.S.)?

Yes No Yes No

I have attached the LOA. (Attach the LOA; if electronic, use normal PDF functions for file attachments.)

Note: If there is no LOA, consult the Form Instructions.

6. Letter of Authorization (LOA), if applicable (generally obtained from the manufacturer of the drug)
FORM FDA 3926 (7/22) Page 3 of 3

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 45 minutes per response, including the 

time to review instructions, search existing data sources, gather and maintain the data needed and complete 

and review the collection of information. Send comments regarding this burden estimate or any other aspect 

of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services 

Food and Drug Administration 

Office of Operations 

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of 

information unless it displays a currently valid OMB number.”